Platinol (cisplatin)

July 31, 2017

Ptac2S Is Better Than Platinol at Reducing Growth Rate of Sarcomatoid Mesothelioma in Mice, Study Shows

News

Ptac2S is more effective than Platinol (cisplatin) at reducing the growth rate of sarcomatoid malignant pleural mesothelioma in mice, according to a study. The finding comes on top of a study showing ... Read more

June 15, 2017June 15, 2017

Chemotherapy Effective in Peritoneal Mesothelioma, But Surgery Also Needs Evaluation, Researchers Say

News

Aggressive malignant peritoneal mesothelioma responds to treatment with Alimta (pemetrexed) and Platinol (cisplatin) chemotherapy, reports a study examining patient outcomes. But more studies are needed to compare chemo’s effectiveness to surgery ... Read more

April 17, 2017May 25, 2017

ADI-PEG 20, Chemo Triple Combo Promotes Cancer Cell Death in Some MPM Patients, Study Shows

News

Depleting the amino acid arginine using a drug called ADI-PEG 20 enhances the efficacy of two well-established chemotherapy medications — Platinol (cisplatin) and Alimta (pemetrexed) — in patients with ASS1-deficient ... Read more

April 6, 2017April 6, 2017

Novocure’s STELLAR Trial Enrolls Last Mesothelioma Patient to Test Tumor Treating Fields, Chemotherapy Combo

News

Novocure has enrolled its last patient in the STELLAR trial (NCT02397928) to assess the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard chemotherapy in newly diagnosed, ... Read more

March 1, 2017

High Temperature Platinol Shows Promise in Treating Malignant Pleural Effusion

News

Injecting heated chemotherapy into the pleural cavity, the region between the two thin layers lining the lungs, is a promising approach for patients who present with malignant pleural effusion (MPE) — ... Read more

January 9, 2017

Eagle Seeks FDA Approval of Ready-to-Dilute Alimta for Mesothelioma, NSCLC

News

Eagle Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its novel ready-to-dilute pemetrexed (Alimta) formulation. The chemotherapy drug, which works by inhibiting the ... Read more

January 3, 2017

Gene Variations May Help Predict Survival in Mesothelioma Patients Receiving Platinum-based Chemotherapy, Study Finds

News

Variations in the immune-system-related FAS ligand (FASL) gene may help predict how long a malignant pleural mesothelioma patient who received platinum-based chemotherapy can survive without the disease progressing. A study in Egypt showed ... Read more

November 18, 2016

Treatment Trio for Mesothelioma Is Safe, Improves Patients’ Survival Rates, According to Trial Data

News

Combining Tumor Treating Fields (TTFields), a method that uses electric fields to disrupt cell division, with standard chemotherapy treatments Alimta (pemetrexed) and Platinol (cisplatin) or Paraplatin (carboplatin) may be a ... Read more

November 15, 2016

Aduro Presents Positive Early Data from Phase 1b Mesothelioma Trial Evaluating Combo Treatment

News

Combining the cancer vaccine CRS-207 with standard of care chemotherapy and cyclophosphamide looks like a promising first-line treatment for patients with unresectable malignant pleural mesothelioma, according to preliminary data from the second cohort of ... Read more

November 9, 2016November 9, 2016

Breast Cancer Treatment, Tamoxifen, Seen to Block Mesothelioma in Early Study

News

Tamoxifen, a medication that blocks the effects of estrogen, worked to prevent the growth of malignant pleural mesothelioma cells cultured in the lab, and to improve the cells’ sensitivity to chemotherapy. Interestingly, ... Read more